MicroPort® Firesorb Bioresorbable Rapamycin Target Eluting Coronary Scaffold System Completes First Successful Implantation in the First FIM Clinical Trial

Beijing, China - On January 18, the initiative meeting for "Evaluating the perspective and the single observation clinical trial for the safety and feasibility of applying Firesorb Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb") in First-in-Man("FIM") coronary heart disease treatment" was held in the interventional catheterization room of Fuwai Hospital of Chinese Academy of Medical Sciences.
Independently researched and developed by Shanghai MicroPort Medical (Group) Co ("MicroPort®"), Firesorb is the second generation of bioresorbable stent. The meeting was chaired by Professor Bo Xu, the director of the catheter room of Fuwai Hospital. The principal investigator Runlin Gao, Vice President Yuejin Yang, Director Shubin Qiao and more than 40 experts attended the meeting. MicroPort® Chief Marketing Officer Bo Peng, Chief Technology Officer Dr. Qiyi Luo, and Senior Vice President Yimin Xu, attended the meeting as well.
During the meeting, Professor Runlin Gao delivered a speech, introducing the unique features of Firesorb stent. He pointed out that the wall of Firesorb is thinner, which is expected to overcome the disadvantage of the first generation of bioresorbable stent. Dr. Qiyi Luo then introduced the performance of Firesorb. Professor Bo Xu explained the clinical trials and standard operating procedures in details, with particular emphasis on the optimized implantation technique of bioresorbable stent.
On January 19, Director Mengyue Yu from Fuwai Hospital selected the first receiver of the clinical trial and successfully implanted one Firesorb stent. Experts spoke highly of Firesorb's excellent crossability, support force, postoperative angiography, and IVUS and OCT angiographic effect.
Firesorb is currently the "first and only" polymer absorbable scaffold. Its wall thickness is only 100μm-125μm. Its design of thin wall allows fast endothelialization after scaffold implantation, which could reduce the risk of postoperative thrombosis. As less material is used to make the scaffold, the degradation period will be further shortened. In addition, the scaffold features targeting elution technique, which makes it the "first and only" absorbable scaffold with targeted release function. Bioresorbable Scaffold System only retains the drug on one surface that contacts blood vessels, reduces the dose of drug, enhances the efficiency of the treatment, and prevents a large amount of drug residual from remaining in the body for a long time. As Firesorb scaffold's first FIM clinical trials was launched, it will lay a good foundation for its following clinical trials.